Axicabtagene Ciloleucel and Tisagenlecleucel for Diffuse Large B-cell Lymphoma


( Last Updated : January 26, 2022)
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1607-000

Details


Question

  1. What is the clinical effectiveness of axicabtagene ciloleucel (axicel) in the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
  2. What is the clinical effectiveness of tisagenlecleucel (tisacel) in the treatment of adult patients with R/R DLBCL ?
  3. What is the comparative clinical effectiveness of axicel versus tisacel in the treatment of adult patients with R/R DLBCL?4. What is the cost-effectiveness of axicel versus tisacel in the treatment of adult patients with R/R DLBCL?

Key Message

Twelve non-randomized studies were identified regarding the clinical effectiveness of axicabtagene ciloleucel in the treatment of adult patient with relapsed or refractory diffuse large B-cell lymphoma.

Seven non-randomized studies were identified regarding the clinical effectiveness of tisagenlecleucel in the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Two non-randomized studies were identified regarding the comparative effectiveness of axicabtagene ciloleucel versus tisagenlecleucel in the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

One economic evaluation was identified regarding the cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel in the treatment of adult patient with relapsed or refractory diffuse large B-cell lymphoma.